Atrial fibrillation is the most common sustained cardiac arrhythmia. The clinical framework is three parallel decisions — stability, rate/rhythm strategy, and stroke prevention — each of which must be addressed independently. Anticoagulation is based on stroke risk, not rhythm status.
CLINICAL PRINTABLE
Coming Soon.
A one-page Atrial Fibrillation Management clinical reference is on the way.
- AF classification: paroxysmal (self-terminating <7 days), persistent (>7 days or requiring cardioversion), long-standing persistent (>12 months), permanent (rhythm control abandoned).
- Evaluate hemodynamic stability first: hypotension, acute pulmonary edema, ischemic chest pain, or syncope attributable to AF requires urgent cardioversion.
- Identify and treat reversible triggers: thyrotoxicosis, infection/sepsis, pulmonary embolism, acute MI, alcohol, stimulants, electrolyte abnormalities, sleep apnea, and pericarditis.
- Assess stroke risk with CHA₂DS₂-VASc score: anticoagulation is generally recommended for score ≥2 in men or ≥3 in women. Assess bleeding risk (HAS-BLED) to identify modifiable bleeding risk factors.
Rate control
Rate control target: resting HR <110 bpm (lenient) or <80 bpm (strict) — lenient control is acceptable in most asymptomatic patients. Beta-blockers and non-dihydropyridine CCBs (diltiazem, verapamil) are first-line. Avoid non-DHP CCBs in HFrEF.
Rhythm control
Rhythm control is preferred for symptomatic patients, younger patients, first-detected AF, and those with tachycardia-mediated cardiomyopathy. Options: cardioversion (electrical or pharmacologic), antiarrhythmic drugs, catheter ablation.
Cardioversion
Electrical cardioversion for hemodynamically unstable AF. For stable AF with duration ≥48 hours (or unknown duration), anticoagulate for ≥3 weeks before cardioversion OR perform TEE to exclude LAA thrombus. Anticoagulate for ≥4 weeks after cardioversion regardless of CHA₂DS₂-VASc score.
Anticoagulation
DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for non-valvular AF. Warfarin for mechanical heart valves or moderate-severe mitral stenosis. Anticoagulation is based on stroke risk — not on whether the patient is in sinus rhythm.
Catheter ablation
Pulmonary vein isolation is increasingly used for symptomatic AF, especially paroxysmal AF. Superior to antiarrhythmic drugs for maintaining sinus rhythm in appropriate patients. Discuss with electrophysiology.
- Follow symptoms, resting/exertional rate, BP, medication tolerance, rhythm burden when relevant, and anticoagulation safety/adherence.
- Persistent symptoms despite adequate rate control should prompt rhythm-strategy discussion and reconsideration of other causes.
- Reassess stroke risk over time as age and comorbidities change — CHA₂DS₂-VASc score increases with age.
- Hemodynamic instability, ongoing ischemic chest pain, acute pulmonary edema/HF, syncope, shock, or other instability attributable to AF requires urgent synchronized cardioversion/acute care.
- Very rapid ventricular response with significant symptoms or failure of safe outpatient rate control warrants acute evaluation.
- Cardiology/electrophysiology referral for catheter ablation candidacy, antiarrhythmic drug management, or complex anticoagulation decisions.
APPLY IT
Stable new AF with HR 128, normal BP, no ischemia/HF, and significant symptoms. Rate control, trigger evaluation, stroke-risk assessment, and rhythm-strategy planning all matter. CHA₂DS₂-VASc score determines anticoagulation.
CHANGE ONE DETAIL
Change one detail — hypotension and acute pulmonary edema attributable to AF — and synchronized cardioversion becomes an emergency pathway. Stability determines the urgency of rhythm control.
Bottom Line
AF is three decisions, not one: stability, symptom/rate-rhythm strategy, and stroke prevention. Anticoagulation is based on stroke risk — not on whether the patient is in sinus rhythm.
EVIDENCE & REFERENCES
- January CT, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019;74(1):104-132. doi:10.1016/j.jacc.2019.01.011
- Hindricks G, et al. 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612